CryoLife (CRY) looks set to open higher after announcing it has received FDA approval for a new...


CryoLife (CRY) looks set to open higher after announcing it has received FDA approval for a new long-term vascular access device (HeRO) which the company will launch in Q4 after validating its manufacturing processes. Shares +4.8% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs